



EQUIMATE ORAL PROGESTAGEN FOR HORSES

Abbey Animal Health Pty Ltd
SAFETY DATA SHEET

Section 1- Identification of Product and Supplier

Supplier Company Details: Abbey Animal Health Pty Ltd

Address: Unit 27/ 1 Maitland place, Norwest NSW, 2153

Telephone Number: 02 8088 0720

Facsimile Number: 02 8088 0721

Emergency Number: Australian Poisons Information Centre: 13 11 26 (24 Hour service).

PRODUCT NAME

EQUIMATE ORAL PROGESTAGEN FOR HORSES

PRODUCT USE

For regulation and control of the breeding cycle of mares and the maintenance of pregnancy in habitually aborting mares, or mares at risk of early abortion.

Section 2- Hazards Identification

Statement of Hazardous Nature

This product is classified as: Classified as hazardous according to the criteria of SWA.

ADG Classification: None allocated. Not a Dangerous Good according to Australian Dangerous Goods (ADG) Code, IATA or IMDG/IMSBC criteria.

SINGAL WORD: WARNING

GHS Classification:

Toxic to Reproduction- Category 2

GHS PICTOGRAM:



HAZARD STATEMENT(S)

First Effective Date: 19th February 2026

H361: Suspected of damaging fertility or the unborn child from repeated oral exposure.

PREVENTION

P202: Do not handle until all safety precautions have been read and understood

P281: Use personal protective equipment as required.

RESPONSE

P308 + P313: IF exposed or concerned: Get medical advice/ attention

STORAGE

P402: Store below 25°C (Air Conditioning).

P410: Protect from light.

DISPOSAL

P501: Dispose of container by wrapping with paper and putting in garbage.

Section 3- Composition / Information on Ingredients

INGREDIENTS:

Chemical Name	CAS No.	Content (%w/w)
Altrenogest	850-52-2	0.22%
Non-hazardous Ingredients	Secret	to 100

This is a commercial product whose exact ratio of components may vary slightly. Minor quantities of other nonhazardous ingredients are also present.

Section 4- First Aid Measures

Call Poisons Information Centre Phone Australia 131 126, if you feel that you may have been poisoned or irritated by this product.

Inhalation: Remove to fresh air and provide oxygen if necessary. If any trouble breathing, get immediate medical attention. Administer artificial respiration if breathing has ceased. If irritation or symptoms occur or persist, consult a doctor.

Skin: While wearing protective gloves, carefully remove any contaminated clothing, including shoes, and wash skin thoroughly with soap and water. If irritation or symptoms occur or persist, consult a doctor.

Eye: Immediately rinse eyes thoroughly with plenty of water. If wearing contact lenses, remove only after initial rinse, and continue rinsing eyes for at least 15 minutes. If irritation occurs or persists, consult a doctor.

Ingestion: Rinse mouth and drink a glass of water. Do not induce vomiting unless under the direction of a qualified medical professional or National Poisons Centre. If symptoms persist, consult a doctor.

Section 5- Fire Fighting Measures

Flammability: Not applicable.

Extinguishing Media: Carbon dioxide (CO₂), extinguishing powder or water spray.

Fire and Explosion Hazards: Not applicable.

Hazardous Combustion Products: None allocated.

Fire Fighting: Wear self-contained breathing apparatus (SCBA) plus protective gloves.

Section 6 - Accidental Release Measures

Personal Precautions and Emergency Procedures: Prevent spilled material from flowing onto adjacent land or into streams, ponds, or lakes. Avoid release to the environment. Wear chemical resistant gloves and overalls, facemask, or goggles. Prevent further spillage. Adsorb spilled product and place in sealable container for disposal. Wash down affected area with water plus detergent. Absorb and collect washings and place in the same sealable container for disposal. Seek advice from the local authority regarding disposal.

Environmental Precautions: Prevent spilled material from flowing onto adjacent land or into streams, ponds, or lakes. Avoid release to the environment.

Section 7 - Handling and Storage

Handling: Avoid contact with skin as ALTRENOGEST is readily absorbed through the skin. Avoid contact with eyes, and mucosa. Keep containers adequately sealed during material transfer, transport, or when not in use.

The following people should not handle ALTRENOGEST:

- women who are, or suspect they are, pregnant.
- people with thrombophlebitis or thromboembolic disorders or cerebral-vascular or coronary artery disease.
- women with carcinoma of the breast.
- people with known or suspected oestrogen dependant neoplasia.
- people with a benign or malignant tumour which developed during the use of oral contraceptives or other oestrogen-containing products.

Avoid contact with skin as ALTRENOGEST is readily absorbed through the skin. Wear gloves. Keep containers adequately sealed during material transfer, transport, or when not in use.

Storage: Store below 25°C (Air conditioning). Protect from light.

Section 8 - Exposure Controls / Personal Protection

Personal Protective Equipment:

Eye Protection: Avoid contact with eyes. Eye protection such as protective glasses or goggles is not usually necessary under normal conditions of use.

Skin Protection: Wear suitable gloves (preferably elbow-length) when skin contact is likely. Wash hands or other exposed areas after handling and use.

Respirator: No special respiratory protection equipment is recommended under normal conditions of use with sufficient ventilation.

Engineering controls: The health hazard risks of handling this material are dependent on many factors, including physical form, duration and frequency of process or task, and effectiveness of engineering controls. Site-specific risk assessments should be conducted to determine the feasibility and the appropriateness of all exposure control measures. Exposure controls for normal operating or routine procedures follow a tiered strategy. Engineering controls are the preferred means of long-term or permanent exposure control. If engineering controls are not feasible, appropriate use of personal protective equipment (PPE) may be considered as alternative control measures. Exposure controls for non-routine operations must be evaluated and addressed as part of the site-specific risk assessment.

Section 9 - Physical and Chemical Properties

Physical state	Oily solution
Colour	Clear, light yellow
pH	Not available
Boiling point	Not available
Flash points	Not available
Solubility(water)	soluble

Section 10 - Stability and Reactivity

Chemical stability: Stable under normal conditions.

Conditions to Avoid: Avoid high temperature. Avoid food products.

Incompatibilities: Strong acids and strong oxidising agents

Hazardous decomposition products: May evolve toxic gases if headed to decomposition.

Section 11 - Toxicological Information

ACUTE TOXICITY

Oral: LD50 175-177 mg/kg in rats. NOEL of 0.03 mg/kg/bw/day.

Dermal: Available data indicates that this product is not harmful. However, this product is readily absorbed through the skin. Accidental absorption by women of childbearing age could lead to a disruption of the menstrual cycle or prolongation of pregnancy.

Section 12 - Ecological Information

No specific environmental toxicity data available. Prevent spills from entering streams, ponds or waterways.

Section 13 - Disposal Considerations

Dispose of container by wrapping with paper and putting in garbage.

Section 14 - Transport Information

No specific transport considerations apply since *EQUIMATE ORAL PROGESTRONE FOR HORSES* is NOT classified as a dangerous good according to Australian Dangerous Goods (ADG) Code.

Section 15 - Regulatory Information

Poisons Schedule: S4

APVMA Approval Number: 88398

Approved pack size: 125 mL, 1L

For more information, please refer to the APVMA approved product label

Section 16 – Other Information

Abbey Animal Health Pty Ltd

Telephone Number: 02 8088 0720

Facsimile Number: 02 8088 0721

Emergency Number: Australian Poisons Information Centre: 13 11 26 (24 Hour service).
This Safety Data Sheet (SDS) summarizes our best knowledge of the health and safety hazard information of the product according to the GHS requirements and how to safely handle and use the product in the workplace.

Each user must review this SDS in the context of how the product will be handled and used in the workplace.

If clarification or further information is needed to ensure that an appropriate risk assessment can be made, the user should contact this company.

***Note: This SDS is valid for 5 years from the effective date.**

First Effective Date: 19th February 2026

Page 5 of 5